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Abstract
Background: Alcohol septal ablation (ASA) is a method of treatment in obstructive hypertrophic car-
diomyopathy (HOCM), but there is little data on the long-term results of ASA and the natural course 
after treatment. The aim of the study was to evaluate the results of ASA in HOCM in multiannual 
observation, and its impact on patient survival, exercise capacity, electrical complications, and changes 
in the anatomy and function of the heart.
Methods: The study evaluated 47 patients with HOCM with a high left ventricular outflow tract (LVOT 
gradient) treated between 1997 and 2014 with ASA. Annual examinations evaluated the clinical condi-
tion, at rest and with exercise electrocardiogram, Holter monitoring, echocardiography, the evolution of 
HOCM towards the dilated form, and the frequency of pacemaker implantation.
Results: The analysis included data from 34 patients under observation for 3 to 17 (mean 10.8) years. 
Their age at procedure was 21–65, a mean of 47 years. All patients had permanently reduced LVOT 
gradient with a mean of 77.36 ± 35.46 to 11.40 ± 10.85 and showed improvement in the performance 
I to II New York Heart Association. Two out of five deaths had possible cardiac etiology. Fifteen patients 
received a pacemaker or cardioverter implants. In 4 subjects the long-term observation revealed new 
wall contractility abnormalities, interpreted as a shift of HOCM to the dilated form.
Conclusions: Alcohol septal ablation permanently eliminated the gradient in LVOT and improved the 
performance of patients, however it did not prevent a shift of HOCM to the dilated form. Pacemaker 
implantations are relatively frequent. (Cardiol J 2017; 24, 2: 125–130)
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Introduction
Hypertrophic cardiomyopathy (HCM) is one 
of the most common heart diseases with a genetic 
background. It occurs in approximately 0.2% of the 
population; approximately 50% can be attributed 
to family burden [1, 2]. The prognosis is relatively 
good for most patients; in mild forms, the risk of 
severe cardiac complications (sudden death, dan-
gerous arrhythmias) is slightly higher than in the 
healthy population. The clinical symptoms most of-
ten occur as a result of left ventricular (LV) diastolic 
dysfunction or heart rhythm disorders. Patients 
with LV outflow track (LVOT) gradient (hyper-
trophic obstructive cardiomyopathy [HOCM]) in 
the course of HCM form a particular group. This 
group of patients often present symptoms of heart 
failure; they have a greatly increased tendency for 
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serious arrhythmia, and may have characteristics 
of low cardiac output, especially during exercise. 
This form of HCM has a significantly worse prog-
nosis regarding life expectancy, and clearly impairs 
patient’s quality of life. While non-obstructive 
forms of HCM medications (beta-blockers, vera-
pamil) may have a positive impact on the clinical 
condition of patients, in the obstructive forms, the 
possibilities of pharmacotherapy are limited. It 
should be noted, that over a period of many years, 
classic HCM can transform into the dilated form 
leading to clinical heart failure, regardless of the 
primary form of the disease [3, 4]. HCM without 
the obstruction of the LVOT does not require 
interventional treatment [5], while a significant 
narrowing of the outflow tract is an indication for 
intervention cardiac surgery (excision of the seg-
ment of the interventricular septum responsible 
for the gradient and possible mitral valve repair), 
or closing — usually by alcohol ablation — the ar-
tery supplying the segment of the interventricular 
septum (IVS) responsible for the gradient, or, when 
there are contraindications to the above mentioned 
procedures, 2-chamber pacemaker implantation 
[6, 7].
The first myectomy operations in HOCM were 
performed in the early 1960s [8]. This procedure 
requires open-heart surgery, and presents  a risk 
of IVS perforation. This procedure does, however, 
offer the possibility of simultaneous repair of the 
mitral valve dysfunction leading to an immedi-
ate reduction of the gradient in LVOT. Inducing 
controlled myocardial infarction in the segment of 
the IVS responsible for the gradient in LVOT by 
the administration of 98% ethanol (alcohol septal 
ablation [ASA]) to the appropriate septal branch of 
the anterior descending artery is an alternative to 
this procedure, and has comparable effectiveness. 
This causes necrosis of the IVS areas supplied by 
this artery, reduction in the thickness and/or the 
formation of scar tissue in this area, and liquidation 
or significant reduction in the gradient in LVOT. 
The most common complication is intraventricu-
lar conduction disturbances requiring pacemaker 
implantation. The first ASA procedures in humans 
were carried out in 1995 [9]. In July 1997 at the Po-
meranian Medical University, Szczecin, Poland the 
first ASA series on 7 patients was performed [10].
Methods
Alcohol septal ablation was applied on patients 
who met the criteria, i.e. obstruction LVOT with 
rest or provoked gradient > 60 mm Hg and the 
clinical symptoms of at least New York Heart 
Association (NYHA) class II despite optimal phar- 
macotherapy. An additional eligibility criterion 
was septal thickness in part responsible for 
a gradient of at least 17 mm and the lack of hemo-
dynamically significant mitral insufficiency. The 
ultimate eligibility criterion for the treatment was 
the anatomy of coronary arteries responsible for 
the gradient in LVOT allowing for the procedure. 
The management protocol included an initial 
clinical assessment (NYHA class, fainting, elec-
trocardiogram [ECG], Holter monitoring, ECG 
exercise test) and echocardiography (gradient 
in LVOT at rest and after provocation, anatomy, 
systolic and diastolic function of the LV, mitral 
valve function) and coronary angiography. The 
control tests included echocardiography, ECG 
and biochemical tests immediately after ASA, and 
during the first week after clinical trial monitor-
ing, echocardiography, Holter monitoring, and 
ECG exercise tests were conducted after 3, 6, 
and 12 months, and then every year thereafter, 
more often if necessary. The first 20 patients 
were subjected to an evaluation of the gradient in 
LVOT by catheterization 6 months after ASA; the 
remaining patients were examined using echocar-
diography. The study analyzed the ECG changes, 
and the occurrence of arrhythmias and/or conduc-
tion disorders, especially in terms of the need 
for electrotherapy, including the implantation of 
a pacemaker or cardioverter-defibrillator (ICD), 
exercise capacity, and changes in echocardiogra-
phy. The analysis also included the symptoms of 
other systems and organs that occurred during the 
observation. From 1997 to the present, 55 peo- 
ple were enrolled for the procedure; ASA was 
performed in 47 (85.5%) patients. Seven patients 
were excluded from the procedure due to coro-
nary artery anatomy; one did not have ablation 
due to advanced atherosclerotic lesions in the 
coronary arteries. The maximum follow-up time 
was 17 years; the mean time was 10.7 years. This 
detailed analysis has included the results from 
patients over a minimum 3 years of observation 
and contains data from 34 patients. Data on the 
length of the observation is shown in Table. 1. 
Treatment was deemed successful if the gradient 
in LVOT was abolished or if it was reduced at rest 
and after provocation to below 30 mm Hg.
The study was approved by the local bioethi-
cal committee and all patients gave their informed 
consent.
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Results
The values of NYHA at the beginning and 
during the follow-up are shown in Table 2. Before 
the procedure episodes of syncope occurred in 
9 (26.5%) patients. There were 5 deaths in the 
whole study group, including 2 of possible cardiac 
etiology (1 patient — sudden death 9 months after 
the procedure, and 1 patient with atrial fibrillation 
12 months after the procedure — possibly stroke). 
Other causes included: in 1 case — a traffic ac-
cident, and in 2 cases — cancer. Contact was lost 
with 12 patients or they refused further follow-up 
examinations. The final analysis included the re-
sults from 34 patients with a mean age of 47 (21–65) 
years at the moment of ASA. At least 3 months 
after ablation all subjects achieved a significant 
improvement in their clinical condition, and almost 
all had NYHA class I.
The results of echocardiography are shown 
in Table 3. All patients demonstrated liquidation 
or significant reduction of the gradient in LVOT, 
though in 1 patient the final result of ASA (complete 
disappearance of the gradient in LVOT) occurred 
only 1 year after procedure and in another it was 
necessary to perform re-treatment and closure of 
another septal artery. In the whole study group 
(excluding the 2 cases mentioned above) the final 
gradient in LVOT established after 3–6 months 
and during further follow-up did not increase. All 
patients manifested increased end-systolic and 
32 end-diastolic dimension of the LV. The thick-
ness of the part located at the base of IVS was 
reduced in all patients; in 12 (35.3%) patients 
a post-infarction scar appeared at the site of abla-
tion. The thickness of the posterior wall of the LV 
in the whole study group was also significantly 
reduced. Basic parameters of the LV diastolic 
function did not change, aside from the extension 
of isovolumetric relaxation time.
New atrioventricular and intraventricular 
conduction disturbances were observed in most 
individuals. During the procedure and in the early 
period after ASA, 24 patients had right bundle 
branch block (RBBB), 5 left bundle branch block 
(LBBB), and 11 patients had various types of 
atrio-ventricular blocks — from I to III grade. In 
12 (35.3%) patients further follow-up revealed 
fixed RBBB and in 3 (8.8%) patients LBBB. Four 
(11.8%) patients required pacemaker implantation 
immediately after ablation, and during further 
follow-ups lasting from 1 to 9 years after ASA 
11 (32.4%) consecutive patients had indications 
for pacemaker implantation. Eleven of the entire 
group of 15 individuals with an implanted pacing 
system were classified for implantation of an ICD 
or a change of a pacemaker to an ICD on the basis 
of existing standards, mainly due to ventricular 
arrhythmia. Atrial fibrillation was reported in 
a total of 12 patients — in 1 it was present before 
ASA, in 11 (32.4%) the disorder was observed 
2–9 years after ASA.
In 12 (35.3%) of the ablated patients from 4 to 
10 years after procedure, the symptoms of heart 
failure increased to class NYHA II. Atrial fibrilla-
tion during follow-up was reported in 9 (26.5%) 
patients, 2–12 years after ASA (mean 8.3 years); 
in 1 person the disorder was observed from the 
beginning of the follow-up. In 3 (8.8%) patients 
Table 1. The duration of follow-up in individual 
patients.
Duration of  
follow-up [years]
Number of  
patients
17 3
16 2
15 3
14 3
13 2
12 3
11 5
10 2
8 2
7 1
6 1
5 5
4 2
3 1
Table 2. The number of patients with New York 
Heart Association (NYHA) performance class  
before alcohol septal ablation, during the period 
of maximum improvement after procedure and 
the last follow-up.
Class Initial  
NYHA
Optimal  
NYHA
Final  
NYHA
III/IV 2
III 16
II/III 10 1 3
II 6 2 14
I/II 4 4
I 27 13
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echocardiography found LV contractility impair-
ment in the area of the inferior wall 7–10 years 
after ASA, as well as a significant decrease in ejec-
tion fraction; in 1 patient there was hypokinesis 
of the para-apical segments of the LV. Coronary 
angiography showed no significant stenosis, and 
therefore an evolution towards the dilated form of 
HCM was reported. During a follow-up of the study 
group the following conditions were diagnosed: 
5 cases of cancer, 3 cases of coronary artery disease 
diagnosed for the first time, 2 — hyperthyroidism 
and 1 — hypothyroidism, 9 — diabetes, and 1 — 
borreliosis.
Discussion
Hypertrophic cardiomyopathy is the most 
common genetic heart disease. It occurs in ap-
proximately 1 per 500 people, and in about 50% 
of these family burden can be established [1, 2]. 
While the non-obstructive form often does not 
cause a significant impairment in exercise capac-
ity (sometimes it even does not impede practising 
sport), the obstruction of the outflow from the LV 
can lead to severe clinical symptoms [6]. Regard-
less of the form, HCM is a significant risk factor for 
sudden cardiac death (SCD), but LVOT obstruction 
significantly increases this risk [11]. Ventricular 
arrhythmias are the most common cause of SCD in 
HCM, especially in the obstructive form [12, 13]. 
In follow-up heart failure may occur due to the pro-
gressive impairment of LV contractility [4, 13, 14].
Liquidation or significant reduction in the 
gradient in LVOT not only improves the quality of 
life of patients with HOCM, but also significantly 
reduces the risk of SCD [15]. For around the last 
20 years ASA (and similar methods of closing the 
coronary arteries which supply the IVS) has been 
an alternative to cardiac surgery in obstructive, 
symptomatic HCM. Although this is not an imme-
diate countermeasure in the reduction or elimina-
tion in the gradient in LVOT [16], it is much less 
invasive and reduces the risks due to a number 
of complications. This method is recommended 
for experienced medical centres with an adequate 
diagnostic base and an experienced team who can 
perform this procedure [6]. Treatments around 
the world have been carried out for about 20 years 
now [9, 17], and at Pomeranian Medical University, 
Szczecin, Poland since 1997 [10]. According to 
literature data the efficacy of ASA is practically 
the same as surgical treatment of HOCM, the 
number of complications is similar with a slightly 
different profile, with indications also the same, so 
the choice of treatment depends on the experience 
of the medical centre [18, 19]. The advantage of 
ASA includes being significantly less invasive; 
a disadvantage is the dependence on the anatomy of 
the coronary arteries, and in some cases an inabil-
ity to improve mitral valve function. The smaller 
Table 3. Basic echocardiographic parameters in the study group.
Initial examination Last follow-up P
Mean ± SD Range Mean ± SD Range
LVOT gradient [mm Hg] 77.36 ± 35.46 30–205 11.40 ± 10.85 1.3–30 < 0.0001
LVSD [cm] 2.23 ± 0.39 1.56–3.18 3.71 ± 0.85 2.3–5.3 < 0.0001
LVDD [cm] 4.18 ± 0.46 3.18–4.93 5.18 ± 0.74 3.7–6.6 < 0.0001
EF [%] 77.94 ± 6.47 62–90 58.76 ± 10.22 32–78 < 0.0001
IVSd [cm] 2.30 ± 0.49 1.59–3.89 1.37 ± 0.45 0.6–2.5 < 0.0001
PWd [cm] 1.40 ± 0.29 1.03–2.26 1.15 ± 0.22 0.9–1.9 < 0.0001
LA [cm] 4.26 ± 0.53 3.01–5.34 4.66 ± 0.76 3.0–6.4 0.015
E [m/s] 0.88 ± 0.24 0.46–1.36 0.79 ± 0.23 0.40–1.69 NS
A [m/s] 0.76 ± 0.26 0.24–1.38 0.76 ± 0.26 0.36–1.61 NS
E/A ratio 1.27 ± 0.49 0.59–2.38 1.13 ± 0.43 0.56–2.09 NS
IVRT [ms] 94.68 ± 20.19 44–132 109.68 ± 30.65 48–180 0.022
DT [ms] 232.94 ± 54.02 133–362 245.62 ± 79.54 127–501 NS
MI scale 1-4 1.71 ± 0.67 0–3 1.81 ± 0.50 1–3 NS
A — mitral A wave; DT — deceleration time of mitral E wave; E — mitral E wave; EF — ejection fraction; IVRT — isovolumetric relaxation 
time; IVSd — intraventricular septum thickness in diastole; LA — left atrium; LVOT — left ventricular outflow tract; LVDD — left ventricular  
diastolic diameter; LVSD — left ventricular systolic diameter; MI — mitral insufficiency; PWd — posterior wall thickness in diastole;  
SD — standard deviation
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dynamics of the gradient reduction in LVOT is 
a secondary issue in the context of the natural his-
tory of the disease. There are few works assessing 
ASA efficacy in the long-term perspective through 
the course of the disease in treated patients and 
other concomitant diseases. Observation of a group 
of patients who undergo this treatment for a period 
more than 10 years is rare [20–24].
 All patients in the present study achieved 
a lasting reduction of the gradient in LVOT below 
30 mm Hg within at least 3 years of observation, 
only 1 person required a repeated treatment after 
1 year. Clinical improvement by at least I NHYA 
class was achieved in all study patients, and the 
effectiveness of the treatment assessed in terms 
of reducing the gradient and a significant improve-
ment in clinical status was practically 100%. Long-
-term observations of patients with HCM showed 
that some of these, regardless of the form of the 
disease, with time manifested impaired LV con-
tractility, its widening, and evolution into a form 
resembling dilated cardiomyopathy. In the study 
group, a similar trend was observed in 4 patients 
who a few years after ablation developed a perma-
nent decrease in ejection fraction with the areas of 
impaired contractility in the absence of coronary 
lesions. In these patients the efficacy of ablation 
was complete, and there was no residual gradient 
in LVOT, so the transition into the dilated form of 
HCM was diagnosed and observed in the natural 
history of this disease.
Indications for electrotherapy is the most im-
portant problem. In HCM, regardless of the form, 
already significant LV hypertrophy is an indication 
for ICD implantation [7, 24]. ASA (slightly more 
often than surgery) which leads to atrioventricular 
and intraventricular disorders (mainly RBBB), and 
in the long term can lead to the need for pacemaker 
implantation. In the study population indications 
for the implantation of a pacemaker or ICD were 
present in 15 people, including 4 in the peri-pro- 
cedure period, and the remaining a period from 
1 to 12 years after ASA. It is of note that eventually 
a device was implanted in as many as 11 patients, 
especially those with electrophysiological indica-
tions requiring ICD.
Limitations on the study
The patient study group was relatively small, 
and the observation period varied. Moreover, there 
was no possibility for a comparison with a similar 
group of patients with HOCM who underwent 
surgical treatment, and those with HOCM and 
a significant gradient in LVOT not undergoing 
interventional treatment. In addition, due to the 
long period of observation and changing equipment 
capabilities, it was not possible to compare more 
advanced echocardiographic parameters based on 
the tissue Doppler. Also, different protocols for 
exercise ECG tests were used. During follow-up 
of the study group, indications for electrotherapy 
changed, as well as electrophysiological treatment 
options. The regularity of control examinations was 
better in patients with an implanted pacing system, 
who were more aware of the need for systematic 
and periodic checks.
Conclusions
1. Alcohol septal ablation is a highly effective 
procedure for improving hemodynamics and 
the clinical status in HOCM for at least several 
years after the procedure. Over a longer period 
the clinical picture is significantly affected by 
diseases of other organs and random events.
2. Interventional treatment does not prevent the 
evolution of HCM into the dilated form.
3. Atrioventricular block requiring pacemaker 
implantation is the most common early com-
plication in the study group. Despite the sig-
nificant improvement in hemodynamics and in 
most cases beneficial LV remodeling, after an 
extended period a large group of patients had 
indications for the implantation of a pacemaker 
or ICD.
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